Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 5/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4175023 | 0.77 | MAPK8 (0.35) | TTKMAPK8ALDH1A1TSHRKCNH2 | |
| SCHEMBL4169058 | 0.77 | TTK (0.35) | TTKMAPK8ALDH1A1LRRK2TSHR | |
| Hydrochloric Acid SCHEMBL5377501 | 0.71 | MAP3K5 (0.51) | TTKMAPK8LRRK2 | |
| Hydrochloric Acid SCHEMBL5386296 | 0.69 | MAP3K5 (0.55) | TTKMAPK8LRRK2 | |
| SCHEMBL4090234 | 0.68 | TTK (0.39) | TTKMAPK8LRRK2 | |
| SCHEMBL4084785 | 0.68 | TTK (0.39) | TTKMAPK8LRRK2 | |
| SCHEMBL4089498 | 0.67 | HRH3 (0.41) | TTKMAPK8KCNH2 | |
| SCHEMBL4083384 | 0.67 | ALDH1A1 (0.57) | ALDH1A1GAATSHRKMT2AKDM4E | |
| SCHEMBL4079986 | 0.67 | TTK (0.38) | TTKMAPK8LRRK2 | |
| SCHEMBL4089562 | 0.66 | HRH3 (0.40) | TTKMAPK8KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2065383-A1 | Indazole compounds and methods of use thereof as protein kinase inhibitors | Signal Pharmaceuticals, Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | BHAGWAT SHRIPAD S | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | WNT3, WNT3A, WNK3 | TTK 401/4885MAPK8 213/4885ALDH1A1 3165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.